Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Nov 1;178(5):1541-54.
doi: 10.1084/jem.178.5.1541.

Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis

Affiliations

Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis

K Ando et al. J Exp Med. .

Abstract

The molecular and cellular mechanisms responsible for cytotoxic T lymphocyte (CTL)-induced immunopathology are not well defined. Using a model in which hepatitis B surface antigen (HBsAg)-specific CTL cause an acute necroinflammatory liver disease in HBsAg transgenic mice, we demonstrate that class I-restricted disease pathogenesis is an orderly, multistep process that involves direct as well as indirect consequences of CTL activation. It begins (step 1) almost immediately as a direct antigen-specific CTL-target cell interaction that triggers the HBsAg-positive hepatocyte to undergo programmed cell death (apoptosis). It progresses (step 2) within hours to a focal inflammatory response in which antigen-nonspecific lymphocytes and neutrophils amplify the local cytopathic effect of the CTL. The most destructive pathogenetic function of the CTL, however, is to secrete interferon gamma when they encounter antigen in vivo, thereby activating the intrahepatic macrophage and inducing a delayed-type hypersensitivity response (step 3) that destroys the liver and kills the mouse. We propose that the principles illustrated in this study are generally applicable to other models of class I-restricted, CTL-induced immunopathology, and we suggest that they contribute to the immunopathogenesis of viral hepatitis during hepatitis B virus infection in humans.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Res. 1983 Jun;43(6):2637-43 - PubMed
    1. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11612-6 - PubMed
    1. Nature. 1983 Sep 15-21;305(5931):239-40 - PubMed
    1. Cancer Res. 1984 May;44(5):1776-83 - PubMed
    1. J Immunol. 1985 Jan;134(1):608-15 - PubMed

Publication types

MeSH terms